Reuters logo
BRIEF-Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse®
October 31, 2017 / 1:00 PM / 25 days ago

BRIEF-Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse®

Oct 31 (Reuters) - Catalyst Pharmaceuticals Inc

* Catalyst Pharmaceuticals completes enrollment in second Phase 3 trial of Firdapse® in patients with Lambert-Eaton Myasthenic Syndrome

* Catalyst Pharmaceuticals Inc - ‍top-line results for Phase 3 trial of Firdapse expected in early December​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below